Antibody-drug Conjugates (ADC)

MC-Gly-Gly-Phe-Gly-cyclopropylacetic acid is a cleavable linker specifically designed for the assembly of antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of cytotoxic agents to antibodies, enabling targeted delivery and enhanced therapeutic efficacy. Its unique structure allows for selective cleavage under physiological conditions, resulting in the release of the drug at the desired site of action. This makes it a valuable tool in the development of innovative cancer therapies.

N-Fmoc-EvcPAB-PNP is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates the controlled release of therapeutic agents upon internalization by target cells, enhancing the targeted delivery of cytotoxic drugs. This compound is essential for research applications involving ADC development and optimization, allowing for the study of efficacy and pharmacokinetics in targeted cancer therapies.

NHPI-PEG3-C2-NHS ester is a non-cleavable three-unit polyethylene glycol (PEG) linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This linker enhances the solubility and stability of ADCs while maintaining their potency. It is particularly useful for facilitating the targeted delivery of cytotoxic agents to cancer cells, making it a valuable tool in cancer research and development of therapeutic strategies.

Fmoc-MeVal-OSu is a specialized linker utilized in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of therapeutic agents to antibodies, enhancing targeted delivery and efficacy in cancer therapies. Fmoc-MeVal-OSu is instrumental in research applications focused on developing novel ADCs for improved treatment outcomes in oncology.

PC-Biotin-PEG4-PEG3-azide is an advanced cleavable linker designed for antibody-drug conjugate (ADC) applications. This reagent features an azide functional group, enabling participation in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with alkyne-containing molecules. Additionally, it can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules possessing DBCO or BCN groups, making it a versatile tool in the creation of targeted therapeutics.

Hydroxy-PEG10-acid is a PEG-based non-cleavable linker designed for the synthesis of Antibody-Drug Conjugates (ADCs). Its primary mechanism involves the formation of stable covalent bonds facilitating the attachment of cytotoxic agents to antibodies. This linker enhances the therapeutic efficacy of ADCs by improving solubility and distribution while minimizing systemic toxicity. It finds application in drug development aimed at targeted cancer therapies and other diseases requiring precise delivery systems.

Me-Tet-PEG8-NHBoc is an ADC linker designed for targeted drug delivery applications. This compound features an 8-unit polyethylene glycol (PEG) chain and a tetrazine moiety, enabling it to undergo inverse electron demand Diels-Alder (iEDDA) reactions with trans-cyclooctenes (TCO). Its unique properties make it suitable for use in antibody-drug conjugates (ADCs), facilitating the precise attachment of therapeutic agents to antibodies while enhancing solubility and stability.

Me-Tet-PEG5-NHS is an ADC linker designed to facilitate site-specific conjugation through its Tetrazine moiety. This compound can engage in a selective inverse electron demand Diels-Alder (iEDDA) reaction with trans-cyclooctene (TCO) derivatives, enabling the formation of stable linkages in antibody-drug conjugates (ADCs). Its five PEG units enhance solubility and promote improved pharmacokinetics, making it suitable for targeted drug delivery applications in cancer research and therapeutic development.

N-Succinimidyl 3-(Bromoacetamido)propionate is a versatile PEG-based linker designed for PROTAC (proteolysis-targeting chimeras) synthesis. This compound facilitates the effective conjugation of small molecules to target proteins, enabling targeted protein degradation. Additionally, it serves as a cleavable linker for the development of antibody-drug conjugates (ADCs), enhancing therapeutic efficacy in cancer research. This reagent is essential for studies focused on protein modulation and targeted therapies.

4-Methyl-4-(pyridin-2-yldisulfanyl)pentanoic acid is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of therapeutic agents to antibodies, promoting targeted delivery and enhanced efficacy in cancer treatment. Its unique disulfide bond allows for selective cleavage within the tumor environment, releasing the cytotoxic drug while minimizing systemic toxicity.

MDTF free acid serves as a non-cleavable linker in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates stable attachment of cytotoxic drugs to antibodies, enhancing targeted delivery to cancer cells while minimizing systemic toxicity. Its application is crucial in the development of effective ADCs for therapeutic research in oncology.

Tetra-O-acetyl-β-D-galactopyranosyl-Ph-CH2-(4-nitrophenyl)carbonate-Fmoc is an innovative ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of active molecules to antibodies, enhancing targeted delivery in therapeutic applications. Its unique chemical structure allows for efficient linkage, making it an essential tool for researchers in drug development focused on precision oncology and targeted therapies.

Hydroxy-PEG3-SS-PEG3-alcohol is a cleavable six-unit polyethylene glycol (PEG) linker designed for applications in antibody-drug conjugate (ADC) synthesis. This compound facilitates the targeted delivery of cytotoxic agents to specific cells by enabling the selective release of the drug upon cellular uptake. Its functionalized structure supports the development of effective and precise biologic therapies within cancer research and drug development.

Me-Tet-PEG4-NH2 is an ADC linker featuring a tetracine group and four polyethylene glycol (PEG) units. This compound facilitates targeted drug delivery through a specific inverse electron demand Diels-Alder (iEDDA) reaction with trans-cyclooctenes (TCOs). Its design enhances the stability and solubility of antibody-drug conjugates, making it a valuable tool for therapeutic applications in targeted cancer treatments and other biomedical research.

DBCO-NHCO-PEG4-acid is a PEG-based linker designed for application in antibody-drug conjugates (ADCs) and PROTAC synthesis. This linker features a DBCO group that participates in strain-promoted alkyne-azide cycloaddition (SPAAC), facilitating selective conjugation with azide-containing molecules. Its chemical properties make it ideal for developing targeted therapeutics that can modulate protein levels in biological research, enhancing experimental outcomes in drug discovery and development.

Glu(OtBu)-Val-Cit-PAB-OH is a non-cleavable ADC linker designed for use in antibody-drug conjugates. This compound facilitates the synthesis of protein-tubulysin conjugates, enabling targeted delivery of cytotoxic agents. Its stability under physiological conditions makes it suitable for various cancer research applications and the development of novel therapeutic strategies.

5-Hydroxypentanoic acid serves as a versatile PROTAC linker, playing a crucial role in targeted protein degradation technology. This compound facilitates the synthesis of PROTAC AR-V7 degrader-1, contributing to innovative research in protein regulation and therapeutic development. Its structural characteristics enhance the design of bifunctional molecules for selective protein degradation, making it a valuable reagent in life sciences research.

Amino-PEG10-OH is a non-cleavable, 10-unit polyethylene glycol (PEG) linker primarily utilized in the development of antibody-drug conjugates (ADCs). This versatile linker also serves a critical role in the synthesis of proteolysis-targeting chimeras (PROTACs). Its hydrophilic properties enhance solubility and stability, making it suitable for diverse applications in chemical biology and therapeutic development.

NO2-SPDMV is a cleavable linker designed for use in antibody-drug conjugates (ADCs). It facilitates the targeted delivery of cytotoxic agents to tumor cells, enhancing therapeutic efficacy while minimizing systemic exposure. This linker is essential for research applications focused on ADC development and optimization.

Mal-Ala-Ala-PAB-PNP is a cleavable linker designed for use in the development of antibody-drug conjugates (ADCs). This compound is engineered to facilitate the selective release of therapeutic agents upon internalization by target cells, enhancing the efficacy of targeted cancer therapies. Its application in ADC synthesis supports the study of targeted delivery mechanisms and the optimization of therapeutic strategies in oncology research.

Me-Tet-PEG5-COOH is an ADC linker designed to facilitate targeted drug delivery through the incorporation of a tetrazine moiety. This compound exhibits high reactivity in inverse electron demand Diels-Alder (iEDDA) reactions with trans-cyclooctene (TCO) derivatives, enabling precise conjugation to therapeutic agents. Its unique structure enhances stability and solubility, making it suitable for applications in antibody-drug conjugate (ADC) development and bioconjugation research.

Gly-amide-OMe-Cbz serves as an ADC linker, facilitating the synthesis of antibody-drug conjugates (ADCs). This compound enables the efficient conjugation of active molecules to antibodies, supporting targeted delivery in therapeutic applications. Its structural features make it a valuable reagent for researchers engaged in the development of innovative ADCs in cancer therapy and other applications.

N-Methyl-N-[(3-methyldithio)-1-oxopropyl]-L-alanine is a specialized linker designed for use in antibody-drug conjugates (ADCs). This compound effectively facilitates the attachment of cytotoxic agents to monoclonal antibodies, enhancing the therapeutic efficacy of targeted cancer treatments. Its unique structure allows for improved stability and release profiles in biological systems, making it a valuable tool for research applications focused on ADC development and optimization.

Benzyl N1-[PEG1-NHS]-N6-(t-Boc)-L-lysinate is an advanced ADC linker designed for effective bioconjugation applications. Its structure features a benzyl group, a PEG unit, an NHS ester, and a t-Boc-protected L-lysine, facilitating the attachment of therapeutic agents to antibodies. This reagent is ideal for research focused on antibody-drug conjugate technology and chemical modifications in various biochemical studies.

Fmoc-Ala-Ala-Pro-OH is a Fmoc-protected tripeptide linker that serves as a crucial component in the development of antibody-drug conjugates (ADCs). This reagent facilitates the conjugation of cytotoxic agents to antibodies, enhancing targeted delivery and therapeutic efficacy. Its unique structure provides stability and reliable linkages, making it an essential tool for research in targeted cancer therapies and other biomedical applications.

4-Pentynoyl-Val-Ala-PAB-PNP is a cleavable linker specifically designed for antibody-drug conjugates (ADCs). This reagent facilitates the synthesis of cryptophycin conjugates and features an alkyne functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azide-containing molecules. Its applications extend to the development of targeted therapeutics, enhancing the efficacy of drug delivery systems.

Endo-BCN-Fmoc-L-Lysine is a specialized linker featuring the bidentate macrocyclic ligand endo-BCN, designed for use in antibody-drug conjugate (ADC) applications. This compound facilitates the synthesis of macrocyclic complexes and participates in click chemistry, where it can react with azide-containing molecules to form stable triazoles without the need for catalysts. Its properties make it particularly valuable in bioconjugation and therapeutic development research.

Mal-amide-PEG8-Val-Cit-PAB-OH is a cleavable ADC linker designed to facilitate targeted drug delivery in antibody-drug conjugates. The maleimide group enables covalent attachment to free thiols present on cysteine residues in proteins, while the hydrophilic PEG spacer enhances solubility and reduces immunogenicity. Upon internalization, the Val-Cit dipeptide is cleaved by cellular proteases, allowing for the efficient release of the therapeutic payload, aided by the PAB functional group. This linker is suitable for use in cancer research and therapeutic development.

Arg-Phe-Asp-Ser is a cleavable linker designed for antibody-drug conjugates (ADCs). It facilitates the release of cytotoxic agents specifically within target cells, thereby enhancing the therapeutic efficacy of ADCs while minimizing off-target effects. This linker is crucial for research applications focused on developing innovative cancer therapies and improving drug delivery systems.

Fmoc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable linker designed for antibody-drug conjugates (ADCs), incorporating a hydrophilic PEG spacer and a Val-Cit-PAB dipeptide. The structure includes a benzylic alcohol on the PAB, facilitating conjugation with reactive drug payloads. Upon Fmoc group removal with piperidine, a primary amine is exposed, enabling further coupling reactions to create amide bonds. The Val-Cit-PAB motif is selectively cleaved by cellular proteases, allowing for the effective release of therapeutic agents within target cells.

N-Boc-N-methyl-D-Valaldehyde functions as an ADC linker, featuring a BOC protecting group that enhances stability during synthesis and application. This compound facilitates the conjugation of antibodies to cytotoxic agents, playing a crucial role in the development of antibody-drug conjugates (ADCs) for targeted cancer therapies. Its structural attributes make it suitable for research applications focused on optimizing ADC design and efficacy.

NHS-cBu-Cit-PAB is a versatile intermediate used in the synthesis of antibody-drug conjugates (ADCs). It functions as an active ester linker that facilitates the conjugation of antibodies to cytotoxic drugs, enhancing targeted delivery and therapeutic efficacy. This reagent is essential for researchers developing ADCs aimed at improving cancer treatment methodologies.

Azido-PEG8-Amido-Val-Cit-PAB is a cleavable linker designed for antibody-drug conjugates (ADCs), targeting Cathepsin B for selective payload release within lysosomes. The Val-Cit moiety ensures that drug release occurs specifically in the intracellular environment, enhancing therapeutic efficacy while minimizing systemic toxicity. The azido group allows for efficient conjugation to DBCO, BCN, or other alkyne-containing molecules through click chemistry. The polyethylene glycol (PEG) spacer improves aqueous solubility, making this reagent suitable for various research applications in drug development.

SCO-PEG2-Maleimide is an ADC linker featuring a maleimide moiety and three polyethylene glycol (PEG) units. This compound serves as a valuable tool for copper-free click chemistry, enabling efficient conjugation in catalyst-free reactions. Its properties facilitate the stability and controlled release of therapeutic agents, making it suitable for drug delivery applications and the development of antibody-drug conjugates.

Azidoacetyl-Val-Cit-PAB-OH is a cleavable linker designed for antibody-drug conjugates (ADCs). This compound facilitates the selective delivery of cytotoxic agents to target cells while minimizing off-target effects. It can be utilized in the development of ADCs for cancer therapy, enhancing therapeutic efficacy through controlled drug release.

Boc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable linker designed for antibody-drug conjugates (ADCs). This compound features a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide, facilitating the attachment of drug payloads through reactive groups such as PNP. The Boc group can be removed via acidic treatment, yielding a primary amine suitable for forming amides through coupling reactions. The Val-Cit-PAB component is preferentially cleaved by cellular proteases, enabling efficient release of the cytotoxic payload within targeted cells.

β-Glu-PNP is an ADC linker that plays a critical role in the synthesis of antibody-drug conjugates (ADCs). It facilitates the stable attachment of cytotoxic drugs to antibodies, allowing for targeted delivery to cancer cells. This compound is essential for research applications focusing on the development and optimization of ADCs in cancer therapies.

MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH is a specialized ADC linker designed to facilitate the conjugation of cytotoxic agents to antibodies. This linker enables the formation of antibody-drug conjugates (ADCs) when combined with Camptothecin, a potent antitumor compound. The resulting drug-linker conjugates enhance targeted delivery and efficacy in cancer research applications, particularly in studies involving Trastuzumab.

NSC 135130 is a BOC-protected ADC linker designed for conjugation with tubulin-targeting inhibitors. This compound facilitates the synthesis of antibody-drug conjugates (ADCs), enhancing the delivery and efficacy of targeted therapies. Its utility in drug development makes it an important reagent for research applications focused on targeted cancer treatments.

N-[S-Trityl-L-cysteinyl]glycine is a cleavable linker specifically designed for antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic drugs in targeted cancer therapy, enhancing the therapeutic efficacy while minimizing off-target effects. Its unique cleavage properties make it an important reagent in the development and optimization of ADCs for research applications in cancer treatment.

SCO-PEG3-Maleimide is a cleavable antibody-drug conjugate (ADC) linker featuring three polyethylene glycol (PEG) units. This compound facilitates copper-free click chemistry, enabling efficient catalyst-free reactions. The maleimide moiety undergoes degradation in aqueous environments, making it suitable for applications in drug delivery research and development.

N-Boc-N-methyl-D-Valinol is an ADC linker featuring a Boc protecting group. This compound plays a crucial role in the development of antibody-drug conjugates (ADCs), facilitating the stable attachment of cytotoxic agents to antibodies. It is particularly valuable in research focused on targeted therapies for cancer, allowing for enhanced specificity and reduced off-target effects in treatment applications.

Fmoc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable linker specifically designed for antibody-drug conjugates (ADCs). This compound features a hydrophilic PEG spacer and a Val-Cit-PAB dipeptide, which enables the selective release of therapeutic payloads inside target cells through proteolytic cleavage. The benzylic alcohol present in the PAB component can readily react with various functional groups for efficient conjugation to drug molecules, while the Fmoc protecting group can be deprotected using piperidine, allowing access to a primary amine for further coupling reactions. This linker is crucial for enhancing the efficacy and specificity of ADCs in biological research and therapeutic applications.

MC-Val-Ala-NHS ester is a cleavable antibody-drug conjugate (ADC) linker that features both a malimide group and an NHS ester group. It facilitates the specific cleavage of Val-Ala linkers by Cathepsin B while the maleimide moiety allows for selective conjugation to thiol groups. The NHS ester efficiently forms stable covalent bonds with amines, such as lysine side chains, under neutral or slightly basic conditions. This reagent is ideal for applications in ADC development, enabling targeted delivery of therapeutic agents.

Benzyl 2-cyclopropyl-2-hydroxyacetate serves as an essential intermediate in the synthesis of antibody-drug conjugate (ADC) linkers. This compound can be effectively coupled with cytotoxic agents like Exatecan and integrated with antibodies, such as hu2F7, to facilitate targeted delivery of therapeutic agents. Its application in ADC development enables enhanced specificity and reduced systemic toxicity for cancer treatment research.

Fmoc-PEG4-GGFG-CH2-O-CH2-Cbz is a cleavable linker designed for antibody-drug conjugates (ADCs), featuring a polyethylene glycol (PEG) moiety composed of four repeating units. This linker facilitates the synthesis of ADCs by enabling stable attachment to antibody molecules while allowing for controlled release of the cytotoxic payload. Its applications include the development of targeted therapies and the study of efficacy and delivery mechanisms in cancer research.

Alkyne-Val-Cit-PAB-OH is a cleavable linker designed for antibody-drug conjugates (ADCs). This compound facilitates the selective release of drug payloads within target cells, enhancing therapeutic efficacy while minimizing off-target effects. Its hydrophilic properties and favorable stability make it suitable for various ADC applications, including cancer therapy and targeted drug delivery research.

Boc-Gly-Sar-OH is a cleavable linker specifically designed for antibody-drug conjugates (ADCs). This compound facilitates the selective release of the cytotoxic agent upon internalization by target cells, enhancing the efficacy of ADCs in cancer therapeutics. Its biochemical properties make it suitable for research applications focused on targeted drug delivery and therapeutic development.

Fmoc-PEG6-Val-Cit-PAB-OH is an enzyme-cleavable linker designed for antibody-drug conjugates (ADCs) that comprises a hydrophilic PEG spacer, a Boc-protected amine, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB allows for conjugation with reactive groups, such as PNP, to facilitate the attachment of drug payloads. The Fmoc protecting group can be removed using piperidine, exposing a primary amine for subsequent amide bond formation. The Val-Cit-PAB moiety is efficiently cleaved by cellular proteases, ensuring targeted release of therapeutic agents within the cells.

NHS-Ala-Ala-Asn-active metabolite is a cleavable linker specifically designed for antibody-drug conjugates (ADCs), targeting kinesin spindle protein (KSP) inhibitors. This reagent facilitates the synthesis of ADCs by ensuring effective drug delivery to cancer cells through selective cleavage. Its key applications include the development and optimization of targeted cancer therapies, enhancing therapeutic efficacy while minimizing off-target effects.